Logo image
Back
Modulation of TcR/CD3-zeta chain expression by a circulating factor derived from ovarian cancer patients
Journal article   Open access   Peer reviewed

Modulation of TcR/CD3-zeta chain expression by a circulating factor derived from ovarian cancer patients

D D Taylor, D P Bender, Ç Gerçel-Taylor, J. Stanson and T L Whiteside
British journal of cancer, Vol.84(12), pp.1624-1629
06/01/2001
DOI: 10.1054/bjoc.2001.1847
PMCID: PMC2363678
PMID: 11401315
url
https://doi.org/10.1054/bjoc.2001.1847View
Published (Version of record) Open Access

Abstract

In women with ovarian cancer, suppression of components of the immune system may promote tumour development. Previous studies in ovarian cancer have demonstrated that decreased expression and function of the T-cell receptor (TcR)-associated signal transducing zeta-chain correlates with deficient immune responsiveness of T cells. In this study, sera and ascitic fluids obtained from woman with advanced ovarian cancer were found to suppress the expression of TcR-associated zeta chain. This suppression of zeta chain expression was dose-dependent and was not observed with biologic fluids obtained from healthy women. The factor responsible for the loss of zeta chain was purified from ascites and characterized as a protein with an appropriate molecular weight of 14 kD. Suppression of T-cell TcR-zeta was specific, since neither Ick nor ZAP-70 expression was affected, while zeta chain was almost completely suppressed. This selective suppression of TcR-zeta expression by the 14 kD ascites-derived factor was shown to operate at the mRNA level. By defining the mechanism through which this protein modulates TcR-zeta chain levels, it might be possible to ultimately prevent the suppressive influences of the tumour microenvironment and restor immune competence in patients with ovarian carcinoma.
Obstetrics and Gynecology

Details

Metrics

14 Record Views
49 Times Cited - Web of Science
Logo image